Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy

Area of Science:

• Biomedical Engineering
• Molecular Oncology
• Nanomedicine

Background:

• Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options and poor patient outcomes.
• Specific microRNAs, known as oncomiRs (e.g., miR-10b and miR-21), play a critical role in GBM progression and invasiveness.
• Targeting these oncomiRs presents a potential strategy for novel GBM therapies.

Purpose of the Study:

• To develop a nanoparticle-based system for the simultaneous inhibition of oncomiRs 10b and 21 in glioblastoma.
• To create bioadhesive nanoparticles (BNPs) with enhanced tumor cell targeting and delivery efficiency.
• To evaluate the therapeutic efficacy of these nanoparticles in combination with temozolomide in preclinical GBM models.

Main Methods:

• Design and synthesis of short gamma-modified peptide nucleic acids (sγPNAs) targeting the seed regions of miR-10b and miR-21.
• Encapsulation of sγPNAs into nanoparticles (NPs) composed of poly(lactic acid) and hyperbranched polyglycerol (PLA-HPG).
• Functionalization of NP surfaces with aldehydes to create aldehyde-functionalized bioadhesive nanoparticles (BNPs) for improved tumor tropism and transfection.
• Administration of sγPNA BNPs combined with temozolomide via convection-enhanced delivery (CED) in orthotopic mouse models of GBM.

Main Results:

• The developed BNPs demonstrated superior transfection efficiency and tumor cell tropism.
• Combined treatment with sγPNA BNPs and temozolomide significantly increased the survival of mice in orthotopic GBM models, exceeding 120 days.
• The study successfully validated the targeting of multiple oncomiRs using sγPNA BNPs as an effective therapeutic strategy.

Conclusions:

• Bioadhesive nanoparticles loaded with anti-seed sγPNAs targeting multiple oncomiRs represent a promising therapeutic approach for glioblastoma.
• This strategy offers potential for personalized GBM treatment by targeting tumor-specific oncomiRs.
• The combination of targeted nanomedicine and chemotherapy shows significant potential to improve GBM treatment outcomes.